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Abstract
In order to characterize the variation in pharmacokinetics of paracetamol across the human age span, we performed a population pharmacokinetic
analysis from preterm neonates to adults with specific focus on clearance. Concentration‐time data obtained in 220 neonates (post‐natal age 1–76 days,
gestational age 27–42 weeks), infants (0.11–1.33 yrs), children (2–7 yrs) and adults (19–34 yrs) were analyzed using NONMEM 7.2. In the covariate
analysis, linear functions, power functions, and a power function with a bodyweight‐dependent exponent were tested. Between preterm neonates and
adults, linear bodyweight functions were identified for Q2, Q3, V1, V2, and V3, while for CL a power function with a bodyweight‐dependent exponent k
was identified (CLi¼CLp (BW/70)k). The exponent k was found to decrease in a sigmoidal manner with bodyweight from 1.2 to 0.75, with half the
decrease in exponent reached at 12.2 kg. No other covariates such as age were identified. A pharmacokinetic model for paracetamol characterizing
changes in pharmacokinetic parameters across the pediatric age‐range was developed. Clearance was found to change in a nonlinear manner with
bodyweight. Based on the final model, dosing guidelines are proposed from preterm neonates to adolescents resulting in similar exposure across all age
ranges.
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Paracetamol or acetaminophen is an antipyretic and
analgesic agent widely used in both adult and pediatric
populations. Typically, paracetamol is given to patients
orally or rectally.1 More recently, an intravenous
formulation of paracetamol has become available, which
was approved for use in term neonates, children and adults
in Europe, even though the USFDA only approved its use
for the treatment of acute pain and fever in adults and
children aged 2 years and older. While intravenous
paracetamol is now being used regularly as an analgesic in
neonates, children and adults,2,3 in the last few years,
intravenous paracetamol in a dose as high as 60mg/kg has
also been proposed as an off‐label treatment of patent
ductus arteriosus in preterm neonates.4–6
To derive evidence based dosing guidelines for
intravenous paracetamol across age ranges including
preterm neonates, term neonates, and infants, information
is needed on its pharmacokinetics. In the past, different
pharmacokinetic models have been reported for paraceta-
mol or its prodrug propacetamol after oral, rectal of
intravenous administration in neonates, infants and/or
children.7–12 These models have however not yet been
used to guide dosing in children of different ages, as the
ofﬁcial label for pediatric intravenous paracetamol has not
changed since these publications. This may be explained
by the fact that all these studies used a bodyweight based 3/4
allometric function combined with an age‐based matura-
tion function to describe changes in paracetamol clearance
across the pediatric age range.7–12 These complex models
may have reduced predictive value, because they use both
bodyweight and age on the same parameter (ie, clearance)
while these covariates are correlated.13,14 There is
therefore a need for validated pediatric models that can
be used to guide dosing, particularly in the youngest age
range including preterm and term neonates.
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Pharmacometrics
In this study, we aimed to develop and validate a
pediatric population pharmacokinetic model for paraceta-
mol on the basis of pharmacokinetic data from eight
previously published paracetamol studies in preterm and
term neonates, infants, children and adults.9,15–21 In the
covariate analysis, linear functions, power functions, and a
power function with a bodyweight dependent exponent22–
25 were tested to capture changes in the different
pharmacokinetic parameters across the pediatric age
range. The results of the model were used to simulate
dose scenarios in all pediatric subpopulations given a
similar target exposure across age.26
Methods
Subjects of the Original Studies
A total of 220 subjects from eight previously published
studies9,15–21 on paracetamol pharmacokinetics were
included in the current study, including neonates (1–76
days), infants (0.11–1.33 years), children (2–7 years), and
adults (19–34 years). No data were available from children
between 8 and 19 years of age. Detailed information on the
studies is given below and summarized in Table 1.
Neonates9,15,16
Study 1: Single dose intravenous propacetamol in neo-
nates15. Thirty preterm (gestational age 27–35 weeks)
and term (gestational age 36–40 weeks) neonates aged
1 day and weighing 0.5–4 kg, who received single dose of
intravenous propacetamol, were included. Propacetamol
dose was 20mg/kg (10mg/kg paracetamol) for the ﬁrst 15
neonates and 40mg/kg (20mg/kg paracetamol) for the
next 15 neonates. Propacetamol bolus infusion was
prepared from a 1 g propacetamol (500mg paracetamol)
powder‐containing vial diluted in 50mL normal saline.
Propacetamol was administered for minor, painful
procedures (ie, insertion of peripheral arterial, venous,
or central venous line, chest tube placement) or as adjuvant
therapy when receiving opioids.
Study 2: Repeated dose intravenous propacetamol in
neonates16. Eighteen preterm and term neonates aged 1–
76 days (postconceptual age 27–42 weeks) and weighing
0.84–4 kg, who received repeated doses of intravenous
propacetamol, were included. The dosing regimen con-
sisted of a loading dose (20mg/kg paracetamol) with a
maintenance dosing of 10mg/kg/dose every 12, 8, or
6 hours for extreme preterm, preterm, and term neonates,
respectively. Propacetamol was prescribed based on a
standardized pain evaluation and analgesic algorithm after
surgery or during speciﬁc medical conditions.
Study 3: Repeated dose intravenous paracetamol in
neonates9. Sixty preterm and term neonates aged 1–28
days and weighing 0.6–4.8 kg, who received repeated
dose intravenous paracetamol, were included. The dosing
regimen consisted of a loading dose (20mg/kg) followed
by a maintenance dose of 5, 7.5, or 10mg/kg every 6 hours
for extremely preterm preterm (<32 weeks postmenstrual
age), preterm (32–36 weeks postmenstrual age) and term
neonates (>36 weeks postmenstrual age), respectively.
Indications for paracetamol administration were medical
(traumatic delivery, necrotizing enterocolitis, prostaglan-
din E2 administration, fever) or surgical (eg, cardiac,
thoracic, abdominal). Samples were collected in the ﬁrst
48 hours after loading dose with a non‐uniform non‐sparse
sampling scheme with a median (range) number of
samples per individual of 7 (2–11).
Infants17,20
Study 4: Repeated dose intravenous propacetamol and
rectal paracetamol in infants17. Twenty‐six infants aged
0.11–1.33 years and weighing 7.5–12.2 kg after major
craniofacial surgery were included in the current analysis.
During surgery, all infants received a rectal loading dose
of 40mg/kg paracetamol 2 hours before anticipated
extubation. On admittance to the pediatric surgical ICU,
the children were randomized to receive either a
15minutes intravenous infusion of 40mg/kg propaceta-
mol (12 subjects) or 20mg/kg paracetamol rectally (14
subjects) every 6 hours. Propacetamol or paracetamol was
administered for analgesia after craniofacial surgery.
Study 5: Repeated dose rectal acetaminophen in infants20.
Nineteen rectally dosed infants, aged 0.67–1.25 years and
weighing 7.9–12.2 kg, were included. These infants
received approximately 2 hours before anticipated ex-
tubation a loading dose of acetaminophen (40mg/kg) that
was administered rectally. Two hours after arrival in the
pediatric surgical ICU, 20‐mg/kg acetaminophen was
administered rectally at 6, 12, and18 hours.
Children
Study 6: Repeated dose rectal acetaminophen in chil-
dren21. Twenty‐nine children, aged 2–7 years and
weighing 14–33 kg, were administered with acetamino-
phen for analgesia after adenotonsillectomy. Patients
received a loading dose of 40mg/kg rectally which was
and followed by a maintenance doses of 30mg/kg rectally
for every 8 hours. The loading dose and maintenance
doses were calculated based on following weight class 14–
16, 17–18, 19–21, 22–23, 24–26, 27–28, 29–31, and 32–
33 kg, resulting in corresponding loading doses of 600,
700, 800, 900, 1000, 1100, 1200, or 1300mg and
corresponding maintenance dose of 450, 525, 600, 675,
750, 825, 900, or 975mg, respectively.
Adults18,19
Study 7: Intravenous infusion of propacetamol in healthy
male adults18. Data from twelve healthy male
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volunteers aged 21–25 years and weighting 63–83 kg
from one sub‐branch (Study I, Occasion B) in the
original study were included in the current analysis.
Each subject was given 1 g of propacetamol HCL
(¼500mg paracetamol) intravenously at a constant
infusion rate over 15minutes.
Study 8: Intravenous infusion of paracetamol in healthy
adults19. Twenty‐six healthy volunteers aged 19–34 years
and weighing 49.2–94 kg were included in the current
analysis. Each subject received ﬁrst a 15minutes infusion
of 2 g of paracetamol (Perfalgan), followed by four
additional 15minutes infusions of 1 g paracetamol each, at
6 hours intervals.
Pharmacokinetic Modeling
Model building. The population pharmacokinetic analysis
was performedwith the non‐linear mixed effects modeling
software NONMEM version 7.2. (ICON Development
Solutions, Ellicott City, MD) using the ﬁrst‐order
conditional estimation method with the interaction
(FOCEI). Pirana27 and R (version 2.15.1) were used to
visualize the output and evaluate the models.
Paracetamol concentrations were logarithmically trans-
formed and ﬁtted simultaneously, since the range in
concentrations was more than 1000‐fold. Model building
was performed in four steps: (1) selection of structural
model, (2) selection of statistical sub‐model, (3) systematic
covariate analysis, (4) model validation. For selection of a
structural or statistical model, a difference in objective
function (OFV) between models of more than 3.84 points
was considered as statistically signiﬁcant (P< .05 assuming
aChi‐square distribution). Next to evaluation of theOFV for
statistical signiﬁcance, the goodness‐of‐ﬁt plots (observed
vs. individual predicted concentrations and vs. population
predicted concentrations, and conditionalweighted residuals
vs. time and vs. population prediction concentrations) of all
data and data stratiﬁed per age category were evaluated.
Beside the OFV and goodness‐of‐ﬁt plots, the total number
of parameters, improvement of the individual concentration‐
time proﬁles, the conﬁdence intervals of the parameter
estimates and the correlation matrix were assessed when
selecting the structural model. For intravenously adminis-
tered propacetamol (72 subjects), 1 unit propacetamol dose
was converted to 0.5 unit of paracetamol as dosing input for
the pharmacokinetic analysis.
Structural model. One, two, and three compartment models
were tested. A three‐compartment model for distribution
and elimination of paracetamol, which was parameterized
in terms of total clearance (CL), volume of distribution of
the central compartment (V1), volume of distribution of
the rapidly‐equilibrating peripheral compartment (V2) and
slowly‐equilibrating peripheral compartment (V3), and
inter‐compartmental CL between central compartment
and two peripheral compartments (Q2, Q3), was superior
over a one compartment model given the criteria as
described under Model building. To describe the process
of rectal absorption for individuals who were given
paracetamol rectally, a rectal deposit compartment was
incorporated into themodel with ﬁrst‐order absorption rate
constant (Ka), bioavailability (F), and lag time (Tlag) as
parameters.
For the pharmacokinetic data from studies in which
propacetamol (an intravenous prodrug of paracetamol)
was used, we tested a pseudo deposit compartment for
propacetamol and its ﬁrst order hydrolysis rate in order to
describe the process of conversion from propacetamol to
paracetamol.20 As the half‐life of the hydrolysis rate
turned out to be very short (<0.0001 hour), this pseudo
deposit compartment was not implemented in the ﬁnal
model.
Statistical model. Interindividual variability in the pharma-
cokinetic parameters was tested in the model assuming
log‐normal distributions, expressed as
ui ¼ uTV  ehi ; hi  Nð0;v2Þ ð1Þ
where ui is the individual pharmacokinetic parameter
value for the ith individual, uTV is the population
pharmacokinetic parameter value or typical value, and
hi is a random variable for the ith individual from a normal
distribution with mean zero and variancev2. In addition to
testing of the inclusion of interindividual variability on
individual parameters, model improvement by inclusion
of covariance between these variability parameters was
tested as well.
Absolute bioavailability was constrained between 0
and 1, as it represents the ratio between the amount of drug
reaching the systemic circulation and the amount of drug
administered.28 Therefore, the interindividual variability
in bioavailability could not be parameterized as described
in Eq. (1) and was parameterized in a model proposed by
Karlsson et al28 using the following function:
Fi ¼ e
ln
TVF
1TVFð Þþhi
1þ eln TVF1TVFð Þþhi
ð2Þ
For the residual error, an additive model for log‐
transformed concentrations was used, which was ex-
pressed as:
logCij ¼ logCpredij þ e; e  Nð0;s2Þ ð3Þ
where Cij is the value of the observed paracetamol
concentration of ith individual at time j, is the value of the
predicted paracetamol concentration of the ith individual
at time j, and Cpredij is a random variable for this
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observation from a normal distribution with mean zero and
variance s2.
Covariate model. Covariates (bodyweight, age) were
plotted independently versus the individual post hoc
parameter estimates and the conditional weighted resid-
uals to evaluate potential relationships. In addition,
gestational age and postmenstrual age were evaluated
for neonates. Potential covariates were separately imple-
mented into the model using a linear function, power
function or a power function with a bodyweight dependent
exponent. This power function with a bodyweight
dependent exponent is called a bodyweight dependent
exponent (BDE) model22 and is shown in Eq. (4), where it
is applied to paracetamol CL.
Cli ¼ Clp  BWi70
 k
; k ¼ k0  kmax  BW
g
i
kg50 þ BWgi
ð4Þ
In Eq. (4), Cli is clearance in the ith individual with
bodyweight BWi; Clp is the clearance in a standardized
adult with a bodyweight of 70 kg; BWi is bodyweight of an
individual i; k is the exponent; k0 is the value of the
exponent at a theoretical bodyweight of 0 kg; kmax is the
maximum decrease of the exponent; k50 is the bodyweight
at which a 50% decrease in the maximum decrease of
exponent value is attained, and g is the Hill coefﬁcient
determining the steepness of sigmoidal decline in the
exponent.22
The signiﬁcance of a covariate for a parameter in the
model was statistically evaluated by the use of the OFV. In
the forward inclusion a P value <.005 was considered as
statistically signiﬁcant while a more stringent P value
<.001 was used in the backward deletion. When two or
more covariates were found to signiﬁcantly improve the
model, the covariate that reduces the OFV the most was
retained in the model. Then the inﬂuence of the remaining
covariates was tested in the covariate‐adjusted model for
signiﬁcance. The ﬁnal covariate model was selected on the
basis of the criteria in this section covariate analysis,
provided that improvements as a result of inclusion of the
covariate in the model were observed as described under
Model Building. Finally, the model was accepted when
the results of the model validation were adequate (see
under Model validation).
Model Validation
The model was validated internally using ﬁve criteria that
were recently proposed for pediatric population model
evaluation.29 (i) The coefﬁcient of variation (CV) of the
parameter estimates either from the covariance step in
NONMEM or from 200 stratiﬁed bootstrap resampling
results is less than 50%, (ii) The basic diagnostic plots and
particularly the plots of the observed versus population
predicted concentrations stratiﬁed for age, are visually
assessed for bias and precision, (iii) The h‐shrinkage is
calculated and evaluated according to Karlsson and
Savic,30 (iv) The individual and population predicted
parameters are plotted against the primary covariate to
evaluate whether the individual predicted parameters are
equally distributed around the population predicted
parameters, (v) The simulation based normalized predic-
tion distribution error (NPDE)31 is calculated based on
2,000 simulations of the entire dataset and is evaluated
visually for bias and precision.31
Simulations on the basis of the final model
Based on the ﬁnal model paracetamol concentration‐time
proﬁles were simulated with NONMEM for children with
a bodyweight of 0.5, 1, 1.5, 2, 3, 5, 8, 9, 15, 20, 35, and
50 kg. Two intravenous administration dosing regimens
were simulated, that is, a standard of care dosing regimen
and a model‐based dosing regimen.
The standard of care dosing regimen for prematurely
born neonates and children was based on the Dutch
Children’s Formulary [5mg/kg every 6 hours (group 1
with weight 0.5, 1, 1.5, and 2 kg)]32 while for term
neonates and children it was based on the ofﬁcial labeling
information in the Netherlands (for term neonates and
children weighing less than 10 kg 7.5mg/kg every 6 hours
(group 2 with weight 3, 5, 8, and 9 kg) and for children
weighing between 10 and 50 kg 15mg/kg every 6 hours
(group 3 with weight 15, 20, 35, and 50 kg).
In the model‐based dosing regimen, recommended
doses were derived for children of all bodyweights on the
basis of a loading dose and a maintenance dose every
6 hours. For this model based dosing regimen, an average
target concentration was needed. Since the target
therapeutic average paracetamol concentration for neo-
nates is unknown and the 6‐hourly 15mg/kg dose is
widely accepted for children weighing more than 10 kg,
we took the average paracetamol concentration reached in
this dose group (ie, 9mg/L) as the target concentration for
the model‐based dosing regimen. On the basis of the 9mg/
L concentration as the target concentration, loading doses,
and maintenance doses of intravenous paracetamol were
optimized based on CL and volume of distribution as
estimated using the ﬁnal model.
Results
For the analysis, data of 220 subjects varying from preterm
and term neonates, infants, children, and adults receiving
paracetamol intravenously or rectally or propacetamol
intravenously were available. An overview of the data of
eight paracetamol studies was summarized in Table 1.
Table 2 presents the results of the ﬁnal model. The
results demonstrated that a three‐compartment structural
model for distribution and elimination of paracetamol was
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superior over a two‐compartment model, based on the
improvement of the goodness of ﬁt plots and a decrease in
OFV value (P< .0001). The population lag time (Tlag) of
the rectal dose was estimated to be 0.409 hour without
interindividual variability. The rectal bioavailability was
estimated to be 0.962 with a large interindividual
variability of 205.9%. The rectal absorption rate constant
(Ka) was estimated to be 0.28 (1/h) with an interindividual
variability of 86.7%.
Concerning the covariate analysis, bodyweight was
identiﬁed a signiﬁcant covariate for all structural
pharmacokinetic parameters except for Ka, F, and Tlag.
For the parameters Q2, Q3, V1, V2, and V3, the inﬂuence
of bodyweight was best described by a linear function
(Table 2). For CL, a power function in which the exponent
k varied with bodyweight in a sigmoidal function (BDE
model, Eq. 4) proved superior over a linear or a power
function with a ﬁxed exponent k (P< .05) according to the
criteria stated in section Methods. The bodyweight‐
dependent exponent k was estimated to decrease from a
value of 1.2 (k0) at the theoretical bodyweight of zero
kilogram to 0.75 (k0–kmax) and reached half this decrease
at 12.2 kilogram (k50) (Table 2). The corresponding age to
the bodyweight of 12.2 kg (k50) proved 2 years in this
study. The minimum exponent (k0–kmax) that is applicable
to the adult range only was ﬁxed to 0.75, since this value
for the exponent was identiﬁed in a separate pre‐analysis
based on adult data only. The Hill factor (g) was found to
be 1.4 and was ﬁxed to this value in the ﬁnal model in
order to get the covariance step (Table 2).
Figure 1 (left panel) shows that on the basis of this BDE
model, the change in individual paracetamol CL over
bodyweight of all individuals of this analysis was very
well captured. As h‐shrinkage was low (12.8%), the
reliability of the individual CL values in the subjects can
be considered high.30 With respect to model validation,
goodness of ﬁt plots stratiﬁed by age (1. birth to 1 month;
2. 1 month to 2 years; 3. 2–12 years; 4. 12–16 years)
showed that the population predicted paracetamol con-
centrations of the ﬁnal model were in good agreement with
the observed paracetamol concentrations for the different
age ranges (Supplemental Figure S1). Concerning the
evaluation of the implementation of the covariate model
for CL in the ﬁnal model by the bodyweight‐dependent
Table 2. Parameter Estimates of the Final Model
Parameter Model estimates RSE Bootstrap mean Bootstrap RSE
Fixed effect
CL ¼TVCL (BW/70)k
TVCL (L/h 70 kg) 17.6 3.2% 17.5 2.8%
k ¼k0–kmax BWg/(k50gþBWg)
kmax 0.45 5.4% 0.44 5.7%
k0–kmax
§ 0.75 FIX — — —
k50 (kg) 12.2 27.2% 28.3 202.9%
g 1.4 FIX — — —
V1 ¼TVV1 (BW/70)
TVV1 (L/70 kg) 25.1 11.2% 24.4 16.1%
Q2 ¼TVQ2 (BW/70)
TVQ2 (L/h 70 kg) 96.8 12.6% 103.7 19.5%
V2 ¼TVV2 (BW/70)
TVV2 (L/70 kg) 36.1 5.5% 36.8 7.3%
Q3 ¼TVQ3 (BW/70)
TVQ3 (L/h 70 kg) 1.4 9.8% 1.4 8.1%
V3 ¼TVV3 (BW/70)
TVV3 (L/70 kg) 21.6 12.8% 22.2 13.9%
Ka (1/h) 0.25 13.8% 0.29 25.9%
Tlag (h) 0.4 5.7 % 0.4 6.4%
F 0.96 8% 0.9 11.7%
Random effect (%)
v CL 35.4% 9.1% 34.6% 17.6%
v V1 63.6% 12.6% 68.4% 36.6%
v Ka 86.7% 14% 95.7% 42.5%
v F 205.9% 76.4% 311% 110%
s 21.4% 8.8% 21.4% 15.9%
k, bodyweight dependent exponent; kmax, maximum decrease of k; k0, value of k at a theoretical bodyweight of 0 kg; k50, the bodyweight at which a 50% decrease in
the maximum decrease of k is attained; g, the Hill coefficient determining the steepness of sigmoidal decline in k; Ka, rectal absorption constant rate; Tlag, lag time
in rectal absorption; F, rectal bioavailability;v, standard deviation of the inter‐individual variability (h); s, standard deviation of the proportional residual error (e);
§ k0–kmax was parameterized as a fixed effect parameter (THETA) in NONMEM.
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exponent (BDE) model, Supplemental Figure S2 shows
that there were no remaining trends in the post hoc eta of
CL versus bodyweight, postnatal age (PNA), postmenst-
rual age (PMA), and gestational age (GA) plots. As the
data of PMA and GA were only available in neonates,
corresponding plots were limited to 50 weeks in the x‐
axes. As a simulation‐based validation method, the
normalized prediction distribution error (NPDE) showed
that paracetamol concentrations in the models were
normally distributed (mean¼0.02462, variance¼ 0.7756,
P< .001) around the median prediction and that there was
no trend in the NPDE versus TIME and versus the
logarithm of the individual predicted concentrations
(Supplemental Figure S3). In addition, the results of the
bootstrap validation of the ﬁnal model are listed in Table 2.
Simulations on the basis of the ﬁnal model for both a
standard of care dosing regimen and amodel‐based dosing
regimen are presented in Figure 2. For the standard of care
dosing regimen, 3 different maintenance doses were used
6 hourly, that is, 5, 7.5, and 15mg/kg for neonates with a
body weight between 0.5–3, 3–10, and children with
weight 10–50 kg, respectively, according to the ofﬁcial
label and the Dutch Childrens Formularium.32 The
simulations upon the standard of care dosing regimen in
group 3 (Figure 2a, bottom row, 10–50 kg) show that on
average a concentration of 9mg/L was attained (Figure 2a,
dotted reference line). For the other groups, a variety of
average concentrations was attained upon this traditional
mg/kg dosing regimen (Figure 2a, upper two rows).
Table 3 shows the loading and maintenance doses for
the model‐based dosing regimen aiming for a concentra-
tion of 9mg/L in all groups with individuals varying in
bodyweight between 0.5 and 50 kg (Figure 2b). Figure 2b
shows the simulated concentrations in all individuals
upon this model‐based dosing regimen. This ﬁgure
illustrates that the target concentration of 9mg/L is
achieved at all weights when using the dosing table
depicted in Table 3.
Discussion
In this meta‐pharmacokinetic analysis we studied the
pharmacokinetics of paracetamol using data from eight
different clinical studies in (pre)term neonates, infants,
children, and adults. The results showed that, develop-
mental changes in CLwere best described on the basis of a
power function with an exponent that varied with
bodyweight. This exponent was found to vary from the
value of 1.2 for neonates to 0.75 for older children and
adults. Using this function, the inﬂuence of bodyweight on
CL was adequately implemented, as changes in CL with
bodyweight were captured in an optimal way (Figure 1,
left panel). This model was conﬁrmed by advanced
internal validation procedures that have been proposed
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Figure 1. Paracetamol clearance (filled circle) against bodyweight of all individuals in this study (left panel) and paracetamol clearance (filled circle)
against bodyweight of all individuals in this study in comparisonwith the results of three previously reportedmodels (letters) (right panel) in log‐log scale.
Solid line: model predicted paracetamol clearance as defined by CLi¼CLp (BW/70)k with k¼ k0–kmax BWg/(k50gþBWg) with parameters as shown
in Table 2. Dashed vertical lines: boundary lines of a range in bodyweight between 7 and 20 kg, which corresponds to a range in postnatal age (PNA)
between 40 days and 7 years in our study dataset. “A”: predicted clearance with model fromAnderson et al10; “Z”: predicted clearance with model from
Zuppa et al11; “M”: predicted clearance with model from Mohammed et al.12
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particularly for pediatric studies where datasets are often
sparse and variability is large.29 Most importantly,
Figure S2 shows that the model can be applied for
individuals with a given bodyweight, age, PMA, or PNA
because the Empirical Bayes Estimates (EBE) based post
hoc interindividual variability of CL had no trend against
either bodyweight or age (including PNA, PMA, and GA)
(Figure S2), conﬁrming that an appropriate ﬁnal model has
been reached.33 These results demonstrate that the
inﬂuence of bodyweight on CL as described by the
highly non‐linear BDE function also captures the
inﬂuence of age (PNA, PMA, or GA) into account.
However, caution is needed for this BDE function in case
of data from obese individuals. There were no obese
individuals in our datasets, therefore our model may not be
valid for obese children.
We compared our model with previously reported
models for paracetamol CL in children as listed in Table 4.
The model reported by Zuppa et al11 mainly studied
children of 7 kg onwards without reporting bodyweight
range. The model reported by Mohammed et al12 studied
children from 1.8 years onwards and the model reported
by Anderson et al also had access to data from a large
number of preterm and term neonates.10The model‐
predicted paracetamol CL from these three models were
derived by applying the respective maturation functions
(Table 4) to the individual data in our analysis. The
predictions were limited to the age range of the original
studies (Table 4) in order to prevent unintended
extrapolations of three literature models. In Figure 1
(right panel), we plotted the model predicted CL from the
three previously published models10–12 and from our
model, against the individual bodyweights of all our
individuals. This ﬁgure shows that the predictions of these
four models were in reasonable agreement with each other,
although different functions and covariates were used. For
the neonatal range, the performance of the Anderson’s
model10 seemed in good agreement with the current
model, even though the two models varied largely in
functions and number of covariates (Table 4). For
individuals aged between 40 days and 7 years with
corresponding body weight between 7kg and 20 kg
(Figure 1 right panel), it seems that the models by Zuppa
et al,11 by Anderson et al,10 and by Mohammed et al12
slightly overestimated CL compared to the estimates
obtained in our study.
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Figure 2. Simulated paracetamol concentration profiles of intravenously administered paracetamol 4 times daily based on a standard of care regimen as
described in section Methods (panel a) and a final model optimized regimen (panel b, Table 3) for neonates with a body weight between 0.5 and 3 kg
(upper row), neonates and infants weighing between 3 and 10 kg (middle row) and childrenwith a weight between 10 and 50 kg (lower row). Solid curves
are paracetamol concentration profiles; horizontal dotted line is the target average paracetamol concentration (9 mg/L) used for the final model
optimized regimen (panel b) which was calculated from the average steady state concentration obtained upon the standard of care dosing regimen in
individuals weighing 15, 20, 35, 50 kg (panel a); MD is the maintenance dose per kilogram; LD is the loading dose per kilogram.
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The BDE function was originally developed on the
basis of a very large and rich dataset from preterm
neonates to adults on propofol.22 Later on, it was applied
for scaling morphine across the entire human lifespan23
and in the current study on paracetamol. Concerning the
results from propofol, morphine, and paracetamol from
the current study, relatively similar values for k were
found (exponent of 1.35 to 0.56, 1.47 to 0.88, and 1.2 to
0.75, respectively). This similarity may be explained by
the fact that glucuronidation is the main pathway for these
drugs uponwhich the question rises “whether this function
could be seen as a semi‐physiological function for
glucuronidation in humans.” For a previously developed
function for morphine glucuonidation from preterm
neonates to 3‐year‐old children, this semi‐physiological
function concept recently was proposed and thereafter
evaluated using physiologically based modeling princi-
ples.34,35 In contrast with the similarity in ranges of
exponent value (k) across three drugs, the current function
for paracetamol differed from propofol and morphine by
the k50 being 12. Two kilograms for paracetamol versus
3.78 and 4.01 kg for propofol and morphine, respectively,
implying that paracetamol CL maturates at a slower rate
than glucuronidation of propofol and morphine. A
possible explanation for this ﬁnding could be that
paracetamol is not entirely metabolized through glucur-
onidation as sulphation plays an important role, particu-
larly in neonates.11 Therefore the current BDE model
probably reﬂects a mixture of maturation processes with
different rates for glucuronidation and sulfation.
Intravenous paracetamol is not licensed for use in
children younger than 2 years of age in the United States.
Table 3. Model‐Based Dosing Regimen of Intravenous Paracetamol Aiming for a Target Paracetamol Concentration of 9mg/L in Individuals Weighing
Between 0.5 and 50 kg
BW (kg) CL (L/h) V (L) t 1/2 (h)
Target Cavg
(mg/L)
MD
(mg)
MD/kg
(mg/kg)
SoCMD/kg
(mg/kg)
Target
reached?
% DIFF
MD/kg
L/M
Ratio
LD
(mg)
LD/kg
(mg/kg)
0.5 0.047 0.18 2.6 9 2.5 5.1 5 Partly þ2% 2.2 5.6 11.2
1 0.11 0.36 2.2 9 6.0 6.0 5 No þ20% 2 12.1 12.1
1.5 0.19 0.54 2.0 9 10.2 6.8 5 No þ36% 1.8 18.3 12.2
2 0.27 0.72 1.8 9 14.8 7.4 5 No þ48% 1.8 26.7 13.3
3 0.47 1.08 1.6 9 25.5 8.5 7.5 Partly þ13% 1.5 38.3 12.8
5 0.96 1.79 1.3 9 51.8 10.4 7.5 No þ39% 1.3 67.3 13.5
8 1.8 2.87 1.1 9 99.1 12.4 7.5 No þ65% 1.3 128.9 16.1
9 2.1 3.23 1.0 9 116.2 12.9 7.5 No þ72% 1.3 151.0 16.8
15 4.1 5.38 0.9 9 221.9 14.8 15 Yes 1% 1.3 288.4 19.2
20 5.7 7.17 0.9 9 307.2 15.4 15 Yes þ3% 1.2 368.7 18.4
35 9.9 12.55 0.9 9 533.0 15.2 15 Yes þ1% 1.2 639.6 18.3
50 13.4 17.93 0.9 9 724.8 14.5 15 Yes 3% 1.2 869.8 17.4
Both maintenance doses administered 4 times daily (MD) and loading doses (LD) are presented. For the maintenance dose expressed per kg (MD/kg) the
difference with a standard of care dosing regimen is given.
BW is body weight; CL is the predicted clearance from final model; V is the predicted volume of distribution from final model; t 1/2¼ ln(2)/(CL/V); Target Cavg is
the target average concentration used for the model‐based dosing regimen which was taken from the average steady state concentrations observed in individuals
weighing 15, 20, 35, 50 kg upon the standard of care dosing regimen; MD is the final model optimized maintenance dose¼Target CavgCL 6 h; MD/kg is the
final model optimized maintenance dose per kilogram¼MD/BW; SoCMD/kg is the maintenance dose per kilogram of the standard of care dosing regimen; Target
Reached is the indication of whether the target concentration is reached with the standard of care doing regimen; %DIFF MD/kg is the change of model based MD/
kg from the SoCMD/kg in percentage¼ 100% (MD/kg—SoCMD/kg)/SocMD/kg; L/M Ratio is the ratio of loading dose to maintenance dose in the model‐based
dosing regimen; LD is the model‐based loading dose¼MD L/M Ratio; LD/kg is the final model optimized loading dose per kilogram.
Table 4. Paracetamol Clearance Across the Human Age Span: Comparison Between Previously Published Reports and the Current Study
Year Author Weight Age‐span Covariate model for clearance
2005 Anderson et al10 0.5–55 kg PCA 27 weeks—14 years CL¼ 16.3 (BW/70)0.75 (1‐0.885exp(PCA in weeks Ln(2)/26.6)
2011 Zuppa et al11 Not reported PNA 29 days—less than 18 years CL¼ 18.4 (BW/70)0.75 (1 0.678 exp(PNA in weeks Ln(2)/41)
2012 Mohammed et al12 13.7–56 kg 1.8–15 years CL¼ 16.51 (BW/70)0.75
This study 0.5–94 kg PCA 27 weeks—34 years CL¼ 17.6 (BW/70)k; k¼ 1.204 0.454BW1.4/(12.21.4þBW1.4)a
CL, paracetamol clearance; BW, bodyweight; PCA, postconceptional age; PNA, postnatal age.
aSee Table 2 for parameter estimates.
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Although intravenous paracetamol is licensed in the EU
for use in children of all age ranges except prematurely
born neonates, there is a debate on the optimal dose for
term neonates and children weighing less than 10 kg
because higher doses than the label recommends are
anticipated.32 Current doses for preterm neonates are
based on expert opinion only.32 Simulation results from
our study conﬁrmed that 15mg/kg maintenance doses are
sufﬁcient for children with a weight between 10 and 50 kg
(Figure 2a and b). However, a dose of 7.5mg/kg is not
enough to reach 9mg/L average paracetamol concentra-
tion in neonates or infants weighing 5, 8, or 9 kg. Besides,
the maintenance dose of 5mg/kg proved to be too low to
reach the target concentration for a prematurely born
neonate weighing 1, 1.5, or 2 kg (Figure 2a). Therefore,
bodyweight adjusted doses were proposed for these two
categories as presented in Table 3. These doses proved to
be in accordance with previous calls for adjustment of the
labeled dose in infants and neonates. Palmer et al36
recommended 10mg/kg 6‐hourly for preterm neonates
with postmenstrual age (PMA) of 28–32 weeks, 12.5mg/
kg 6‐hourly for neonates with PMA of 32–36 weeks and
15mg/kg 6‐hourly for neonates with PMA more than
36 weeks. Allegaert et al9 suggested a dosing regimen of
10mg/kg every 6 hours within the age range 32–44 weeks
PMA. Although ﬁnal dose recommendations should
consider not only the pharmacokinetics but also the
pharmacodynamics and safety of paracetamol in neonates
and infants, the current model can be the ﬁrst step towards
an evidence based dosing in children of all ages including
preterm and term neonates. In addition, this BDE model
can also be used to derive adjusted pediatric doses by use
of Table 3 in which another target concentration (higher or
lower than 9mg/L) can easily be ﬁlled in, for instance
when another therapeutic target concentration for a
speciﬁc age category would be identiﬁed.
Conclusions
A pharmacokinetic model for paracetamol characterizing
changes in pharmacokinetic parameters across the entire
human lifespan (preterm and term neonates, infants,
children, and adults) was developed in which CL was
found to change in a highly non‐linear manner with
bodyweight. The results may provide insight in the exact
relation between weight and CL and as such provide a
guide for individualized dosing in children. Once the
therapeutic target concentration is known, corresponding
appropriate doses can be easily calculated based on this
model.
Acknowledgments
This study was performed within the framework of Top Institute
Pharma project number D2‐104. The clinical research of Karel
Allegaert is supported by the Fund for Scientiﬁc Research,
Flanders (Fundamental Clinical Investigatorship 1800209N).
The authors would like to thank Bristol‐Myers Squibb for
sharing adult data of paracetamol (Gregoire et al).
Declaration of Conflicting Interests
All authors declare no conﬂict of interest.
References
1. Oscier C, Bosley N, Milner Q. Paracetamol ‐ a review of three routes
of administration. Update Anaesth. 2007;23:112–114.
2. PalmerGM,Chen SP, SmithKR, HardikarW. Introduction and audit
of intravenous paracetamol at a tertiary paediatric teaching hospital.
Anaesth Intensive Care. 2007;35(5):702–706.
3. Jahr JS, Lee VK. Intravenous acetaminophen. Anesthesiol Clin.
2010;28(4):619–645.
4. Hammerman C, Bin‐Nun A, Markovitch E, Schimmel MS, Kaplan
M, Fink D. Ductal closure with paracetamol: a surprising new
approach to patent ductus arteriosus treatment. Pediatrics.
2011;128(6):e1618–e1621.
5. Yurttutan S, Oncel MY, Arayici S, et al. A different ﬁrst‐choice drug
in the medical management of patent ductus arteriosus: oral
paracetamol. J Matern Fetal Neonatal Med. 2013;26(8):825–827.
6. Allegaert K, Anderson B, Simons S, van Overmeire B. Paracetamol
to induce ductus arteriosus closure: is it valid? Arch Dis Child.
2013;98(6):462–466.
7. Anderson BJ, Woollard GA, Holford NH. A model for size and age
changes in the pharmacokinetics of paracetamol in neonates, infants
and children. Br J Clin Pharmacol. 2000;50(2):125–134.
8. Anderson BJ, van Lingen RA, Hansen TG, Lin YC, Holford NH.
Acetaminophen developmental pharmacokinetics in premature
neonates and infants: a pooled population analysis. Anesthesiology.
2002;96(6):1336–1345.
9. Allegaert K, Palmer GM, Anderson BJ. The pharmacokinetics of
intravenous paracetamol in neonates: size matters most. Arch Dis
Child. 2011;96(6):575–580.
10. Anderson BJ, Pons G, Autret‐Leca E, Allegaert K, Boccard E.
Pediatric intravenous paracetamol (propacetamol) pharmacokinet-
ics: a population analysis. Pediatr Anaesth. 2005;15(4):282–292.
11. Zuppa AF, Hammer GB, Barrett JS, et al. Safety and population
pharmacokinetic analysis of intravenous acetaminophen in neonates,
infants, children, and adolescents with pain or Fever. J Pediatr
Pharmacol Ther. 2011;16(4):246–261.
12. Mohammed BS, Engelhardt T, Cameron GA, et al. Population
pharmacokinetics of single‐dose intravenous paracetamol in
children. Br J Anaesth. 2012;108(5):823–829.
13. Bonate PL. The effect of collinearity on parameter estimates in
nonlinear mixed effect models. Pharm Res. 1999;16(5):709–717.
14. Khandelwal A, Hooker AC, Karlsson MO. Inﬂuence of correlated
covariates on predictive performance for different models. PAGE 20
(2011) Abstr 2220; 2011.
15. Allegaert K, Van der Marel CD, Debeer A, et al. Pharmacokinetics of
single dose intravenous propacetamol in neonates: effect of gestational
age. Arch Dis Child Fetal Neonatal Ed. 2004;89(1):F25–F28.
16. Allegaert K, Anderson BJ, Naulaers G, et al. Intravenous
paracetamol (propacetamol) pharmacokinetics in term and preterm
neonates. Eur J Clin Pharmacol. 2004;60(3):191–197.
17. Prins SA, Van Dijk M, Van Leeuwen P, et al. Pharmacokinetics and
analgesic effects of intravenous propacetamol vs rectal paracetamol
in children after major craniofacial surgery. Pediatr Anaesth.
2008;18(7):582–592.
18. Depre M, van Hecken A, Verbesselt R, Tjandra‐Maga TB, Gerin M,
de Schepper PJ. Tolerance and pharmacokinetics of propacetamol, a
paracetamol formulation for intravenous use. Fundam Clin
Pharmacol. 1992;6(6):259–262.
10 The Journal of Clinical Pharmacology / Vol XX No XX (2014)
19. Gregoire N, Hovsepian L, Gualano V, Evene E, Dufour G, Gendron
A. Safety and pharmacokinetics of paracetamol following intrave-
nous administration of 5 g during the ﬁrst 24 h with a 2‐g starting
dose. Clin Pharmacol Ther. 2007;81(3):401–405.
20. van der Marel CD, van Lingen RA, Pluim MA, et al. Analgesic
efﬁcacy of rectal versus oral acetaminophen in children after major
craniofacial surgery. Clin Pharmacol Ther. 2001;70(1):82–90.
21. van der Marel CD. Paracetamol, Widely used Hardly understood.
Rotterdam: Erasmus University Medical Center; 2003.
22. Wang C, Peeters MY, Allegaert K, et al. A bodyweight‐dependent
allometric exponent for scaling clearance across the human life‐span.
Pharm Res. 2012;29(6):1570–1581.
23. Wang C, Sadhasivam S, Krekels EH, et al. Developmental changes
in morphine clearance across the entire paediatric age range are best
described by a bodyweight‐dependent exponent model. Clin Drug
Invest. 2013;33(7):523–534.
24. Bartelink IH, Boelens JJ, Bredius RG, et al. Body weight‐dependent
pharmacokinetics of busulfan in paediatric haematopoietic stem cell
transplantation patients: towards individualized dosing. Clin
Pharmacokinet. 2012;51(5):331–345.
25. Ince I, de Wildt SN, Wang C, et al. A novel maturation function for
clearance of the cytochrome P450 3A substrate midazolam from
preterm neonates to adults. Clin Pharmacokinet. 2013;52(7):555–565.
26. Allegaert K, Naulaers G, Vanhaesebrouck S, Anderson BJ. The
paracetamol concentration‐effect relation in neonates. Paediatr
Anaesth. 2013;23(1):45–50.
27. Keizer RJ, Karlsson MO, Hooker A. Modeling and Simulation
Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose.
CPT: Pharmacomet Syst Pharmacol. 2013;2:e50.
28. Karlsson MO, Jonsson EN, Wiltse CG, Wade JR. Assumption
testing in population pharmacokinetic models: illustrated with an
analysis of moxonidine data from congestive heart failure patients. J
pharmacokinet biopharm. 1998;26(2):207–246.
29. Krekels EH, van Hasselt JG, Tibboel D, Danhof M, Knibbe CA.
Systematic evaluation of the descriptive and predictive performance
of paediatric morphine population models. Pharm Res. 2011;28(4):
797–811.
30. Karlsson MO, Savic RM. Diagnosing model diagnostics. Clin
Pharmacol Ther. 2007;82(1):17–20.
31. Brendel K, Comets E, Laffont C, Laveille C, Mentre F. Metrics for
external model evaluation with an application to the population
pharmacokinetics of gliclazide. Pharm Res. 2006;23(9):2036–
2049.
32. Paracetamol NKFK. (Perfalgan) Dutch Childrens Formularium.
2013; http://www.kinderformularium.nl/search/stof.php?id¼82
33. Mandema JW, Verotta D, Sheiner LB. Building population
pharmacokinetic–pharmacodynamic models. I. Models for covariate
effects. J Pharmacokinet Biopharm. 1992;20(5):511–528.
34. Krekels EHJ, Neely M, Panoilia E, et al. From pediatric covariate
model to semiphysiological function for Maturation: Part I‐
extrapolation of a covariate model from morphine to zidovudine.
CPT: Pharmacomet Syst Pharmacol. 2012;1:e9.
35. Krekels EHJ, Johnson TN, den Hoedt SM, et al. From pediatric
covariate model to semiphysiological function for maturation: Part
II‐sensitivity to physiological and physicochemical properties. CPT:
Pharmacomet Syst Pharmacol. 2012;1:e10.
36. Palmer GM, Atkins M, Anderson BJ, et al. I.V. acetaminophen
pharmacokinetics in neonates after multiple doses. Br J Anaesth.
2008;101(4):523–530.
Supporting Information
Additional supporting information may be found in the
online version of this article at the publisher’s web‐site.
Wang et al 11
